Tumor immunotherapy is a promising therapeutic strategy for patients with advanced
cancers. T cells are key mediators of antitumor function that specifically recognize and react …

The emergence of immunotherapies has definitely proven the tight relationship between
malignant and immune cells, its impact on cancer outcome and its therapeutic potential. In …

Glycolysis, including both lactate fermentation and pyruvate oxidation, orchestrates CD8+ T
cell differentiation. However, how mitochondrial pyruvate metabolism and uptake controlled …

Chimeric antigen receptor (CAR) costimulatory domains derived from native immune
receptors steer the phenotypic output of therapeutic T cells. We constructed a library of …

Although CD8+ T cells undergo autonomous clonal proliferation after antigen stimulation in
vivo, the expansion of activated CD4+ T cells is limited by intrinsic factors that are poorly …

Chimeric antigen receptors (CARs) have an antigen-binding domain fused to
transmembrane, costimulatory, and CD3ζ domains. Two CARs with regulatory approval …

Programmed death-1 receptor ligand 1 (PD-L1) is a promising therapeutic target in
aggressive cancers. However, immune landscapes and cancer hallmarks of human PD-L1+ …

Histone deacetylases (HDAC) are therapeutic targets in multiple cancers. ACY241, an
HDAC6 selective inhibitor, has shown anti-multiple myeloma (MM) activity in combination …

Coordinate control of T cell proliferation, survival, and differentiation are essential for host
protection from pathogens and cancer. Long-lived memory cells, whose precursors are …

CD8+ T cell differentiation into effector cells is initiated early after antigen encounter by
signals from the T cell antigen receptor and costimulatory molecules. The molecular …